A speaker at this year's Biology of Genomes meeting discussed marrying genomics approaches such as CRISPR and single-cell sequencing to study disease causality.
The company plans to take a tiered approach to assay development, targeting its first test to 10 viruses commonly detected in transplant patients.
The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.
While the company's product and product-related revenues rose 54 percent, its collaborative development program revenues fell 78 percent.
The company reported $1.9 million in Q1 revenues amid a widened net loss of $7.9 million that was driven by increased operating expenses.
The two Netherlands-based firms will market their joint offering to pharmaceutical companies and others researching immune system-related diseases.
Genetic material found in tooth samples from the Bronze Age, Iron Age, and Medieval period points to migrations from Siberia at the Bronze Age-Iron Age transition.
Two new studies of stage I to III CRC suggest that the presence of ctDNA in the months after surgery or chemotherapy can help identify patients who go on to relapse.
Take2 Health plans to launch an nasopharyngeal carcinoma early detection test in the next several months in Hong Kong and southern China.
The company will offer 3.75 million shares of its common stock at $21 per share.
The California startup is about to launch its first product, a noninvasive prenatal screening test for recessive single-gene disorders called Unity.
Research led by Stanford's Mike Snyder has inspired a new company, Q Bio, offering genomic and other analyses, and longitudinal tests to track individuals' health.
New methods for spatial transcriptomic profiling include a sequential FISH-based method and one that makes use of DNA-barcoded bead arrays.
Researchers built a single-cell gene expression atlas of premalignant lesions and early gastric cancer to find shifts that could portend disease progression.
Investigators used gene panel sequence data to look at rare de novo variant frequencies in potential risk genes for neurodevelopmental disorders with epilepsy.
The company will use the proceeds to expand its R&D capabilities and its commercial operations.
Using exome or transcriptome data from more than 400 metastatic, castration-resistant prostate cancer cases, researchers identified survival-related alterations in the RB1 gene.
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
The next-generation sequencing assay is intended for use in identifying patients with ROS1, NTRK1-3, and ALK gene fusions in advanced solid tumors.
The company recognized total first quarter revenues of $16.4 million and a net loss of $30.3 million.
The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.
An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.
The US Department of Agriculture presents a new blueprint for animal genomic research.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.